Clinical study of sequential targeted drug therapy following chemotherapy in treatment of elderly advanced non-small cell lung cancer patients with acquired epidermal growth factor receptor-tyrosine kinase inhibitor resistance
10.3760/cma.j.issn.1006-9801.2018.09.010
- VernacularTitle:化疗序贯靶向药物治疗表皮生长因子受体-酪氨酸激酶抑制剂获得性耐药老年晚期非小细胞肺癌患者临床研究
- Author:
Yan XU
1
;
Chunxiang TIAN
;
Wu LIU
;
Chunyan LI
Author Information
1. 266042,青岛市中心医院 青岛市肿瘤医院肿瘤放疗二科
- Keywords:
Carcinoma,non-small-cell lung;
Drug therapy,combination;
Drug resistance,neoplasm
- From:
Cancer Research and Clinic
2018;30(9):617-620
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and adverse effects of sequential administration of epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)following pemetrexed combined with cisplatin in elderly advanced non-small cell lung cancer(NSCLC)patients with acquired EGFR-TKI resistance.Methods A total of 97 elderly patients with advanced NSCLC confirmed with pathology or cytology in Qingdao Center Hospital from March 2012 to March 2014 were devided into control group and research group according to treatment methods.The control group received pemetrexed 500 mg/m2day 1 and cisplatin 75 mg/m2day 1-3,and the research group received pemetrexed 500 mg/m2and cisplatin 75 mg/m2,then received sequential administration of EGFR-TKI(gefitinib 250 mg/d or elotinib 150 mg/d or icotinib 375 mg/d).The efficacy,progression-free survival(PFS)and toxicity in both groups were compared.Results The disease control rate of control group and research group were 41.67％(20/48)and 65.31％(32/49),the difference was statistically significant(χ2=5.448,P =0.020).The objective response rate of control group and research group were 16.67％(8/48)and 28.57％(14/49),the difference was not statistically significant(χ 2=1.960,P=0.162).The median PFS time of control group and research group were 4.0 months(95％CI 3.554-4.446)and 4.5 months(95％CI 3.902-5.098),the difference was statistically significant(χ 2= 3.936,P= 0.047).There was no significant difference in adverse reactions between the two groups(P＞ 0.05).Conclusion The sequential administration of EGFR-TKI following pemetrexed combined with cisplatin is suitable for the treatment of elderly advanced NSCLC patients with acquired EGFR-TKI resistance.
